After Shareholder Vote, Arris s Acquisition of Sequana Therapeutics Is Concluded | GenomeWeb

SOUTH SAN FRANCISCO, Calif.--After shareholders of Sequana Therapeutics voted overwhelmingly in favor of the move earlier this month, Arris Pharma ceutical here has completed its acquisition of the leading genomics firm, with the new, combined entity taking on the name AxyS Pharmaceuticals. Then on January 14, AxyS announced that it has launched a new Advanced Tech nologies Division to focus on commercializing the company's capabilities in combinatorial chemistry, pharmacogenomics, and its patented Delta technology.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.